Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Rofecoxib | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Rofecoxib | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Rofecoxib | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Rofecoxib | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Rofecoxib | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | Rofecoxib | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Rofecoxib | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Rofecoxib | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Rofecoxib | hsa04062 | Chemokine signaling pathway | 9.23E-03 | 10 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Rofecoxib | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | | Rofecoxib | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | | Rofecoxib | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | | Rofecoxib | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Rofecoxib | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Rofecoxib | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | Rofecoxib | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Rofecoxib | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | Rofecoxib | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Rofecoxib | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | Rofecoxib | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Rofecoxib | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Rofecoxib | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Rofecoxib | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Rofecoxib | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | | Rofecoxib | hsa04613 | Neutrophil extracellular trap formation | 4.93E-02 | 8 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, C5AR1 | More | | Rofecoxib | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | | Rofecoxib | hsa04650 | Natural killer cell mediated cytotoxicity | 2.02E-03 | 9 | P16298, P50591, O60880, P20963, Q02750, Q13241, P26718, P26717, P26715 | PPP3CB, TNFSF10, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KLRC1 | More | | Rofecoxib | hsa04657 | IL-17 signaling pathway | 1.36E-02 | 5 | O00463, Q16539, P49841, P14780, P01375 | TRAF5, MAPK14, GSK3B, MMP9, TNF | More | | Rofecoxib | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 7 | Q04759, P20963, P09693, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, STAT4, GATA3, TBX21, HLA-DOB | More | | Rofecoxib | hsa04659 | Th17 cell differentiation | 9.58E-04 | 13 | Q04759, P19174, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, PLCG1, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Rofecoxib | hsa04660 | T cell receptor signaling pathway | 1.00E-02 | 7 | Q9UDY8, Q04759, P10747, Q08881, P20963, P09693, P01732 | MALT1, PRKCQ, CD28, ITK, CD247, CD3G, CD8A | More | | Rofecoxib | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Rofecoxib | hsa04664 | Fc epsilon RI signaling pathway | 2.40E-03 | 7 | P01375, Q16539, P42338, Q9UQC2, P07948, P19174, P09917 | TNF, MAPK14, PIK3CB, GAB2, LYN, PLCG1, ALOX5 | More | | Rofecoxib | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | Rofecoxib | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Rofecoxib | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Rofecoxib | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Rofecoxib | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Rofecoxib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Rofecoxib | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | Rofecoxib | hsa05163 | Human cytomegalovirus infection | 2.80E-02 | 6 | P01375, P49841, P14778, P25025, Q16539, O00463 | TNF, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | Rofecoxib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Rofecoxib | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | Rofecoxib | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | Rofecoxib | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | | Rofecoxib | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | Rofecoxib | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Rofecoxib | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Rofecoxib | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Rofecoxib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.84E-02 | 5 | P20963, P09693, O60603, P10747, Q04759 | CD247, CD3G, TLR2, CD28, PRKCQ | More | | Rofecoxib | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | | Rofecoxib | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Rofecoxib | hsa05332 | Graft-versus-host disease | 3.45E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | | Rofecoxib | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |